×

Signal Genetics Obtains New York State Approval for MyPRS(R) Multiple Myeloma Prognostic Test

NEW YORK, June 30, 2014 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (Nasdaq:SGNL) (Signal), a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced New York State Department of Health approval of its MyPRS (Myeloma Prognostic Risk Signature®) test.

"With approval of MyPRS by the New York State Department of Health, we are now available in all 50 U.S. states to provide physicians and patients with a service to make better informed decisions when treating newly diagnosed or relapsed multiple myeloma. Most importantly, we will be entering a state with significant market opportunity," said Sam Riccitelli, Signal President and CEO. "This approval makes MyPRS available to all of the more than 24,000 multiple myeloma patients diagnosed in the U.S. each year – further establishing our prognostic as a standard tool in the management of this difficult to treat disease."

MyPRS is a microarray-based gene expression profiling assay used to assist in treatment planning and disease management of patients with multiple myeloma and related disorders. By profiling the genomes of patients' isolated plasma cells, MyPRS generates a personalized prognostic score and molecular subtype that may inform each patient's specific therapeutic alternatives. Extensive clinical trials and international peer-reviewed studies reinforce the clinical validity and utility and prognostic performance of the test.

MyPRS will be available in New York immediately. New York physicians may contact Signal customer service at 501.686.8985 or customerservice@signalgenetics.com to order the test.

About Signal Genetics, Inc.

Signal Genetics, Inc., headquartered in New York, N.Y., is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. Our mission is to develop, validate and deliver innovative diagnostic services that enable better patient-care decisions. We were founded in January 2010 and became the exclusive licensee in our licensed field to the renowned research on multiple myeloma performed at the University of Arkansas for Medical Sciences, or UAMS, in April 2010.

CONTACT: INVESTOR CONTACT: The Ruth Group David Burke Tel: 646-536-7009 dburke@theruthgroup.comSource:Signal Genetics, Inc.